Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity

Emily B. Martin, Angela Williams, Craig Wooliver, R. Eric Heidel, Sarah Adams, John Dunlap, Marina Ramirez-Alvarado, Luis M. Blancas-Mejia, Ronald H. Lands, Stephen J. Kennel, Jonathan S. Wall

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed of proteinaceous fibrils and extracellular matrix proteins found in all patients with AL and in ~10±30% of patients who presented with MM. Amyloid deposits systemically in multiple organs and tissues leading to dysfunction and ultimately death. The overall survival of patients with amyloidosis is worse than for those with early stage MM. Methods and findings We have developed a sensitive binding assay quantifying the recruitment of full length, patient-derived LC proteins by synthetic amyloid fibrils, as a method for studying their amyloidogenic potential. In a survey of eight urinary LC, both AL and MM-associated proteins were recruited by synthetic amyloid fibrils; however, AL-associated LC bound significantly more efficiently (p < 0.05) than did MM LCs. The LC proteins used in this study were isolated from urine and presumed to represent a surrogate of serum free light chains. Conclusion The binding of LC to synthetic fibrils in this assay accurately differentiated LC with amyloidogenic propensity from MM LC that were not associated with clinical amyloid disease. Notably, the LC from a MM patient who subsequently developed amyloid behaved as an ALassociated protein in the assay, indicating the possibility for identifying MM patients at risk for developing amyloidosis based on the light chain recruitment efficacy. With this information, at risk patients can be monitored more closely for the development of amyloidosis, allowing timely administration of novel, amyloid-directed immunotherapiesthis approach may improve the prognosis for these patients.

Original languageEnglish (US)
Article numbere0174152
JournalPLoS One
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

myeloma
amyloid
Amyloid
Light
amyloidosis
Multiple Myeloma
Proteins
proteins
Amyloidosis
assays
Assays
Immunoproliferative Disorders
extracellular matrix
prognosis
urine
Myeloma Proteins
death
Extracellular Matrix Proteins
Amyloid Plaques
Pathology

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity. / Martin, Emily B.; Williams, Angela; Wooliver, Craig; Heidel, R. Eric; Adams, Sarah; Dunlap, John; Ramirez-Alvarado, Marina; Blancas-Mejia, Luis M.; Lands, Ronald H.; Kennel, Stephen J.; Wall, Jonathan S.

In: PLoS One, Vol. 12, No. 3, e0174152, 01.03.2017.

Research output: Contribution to journalArticle

Martin, EB, Williams, A, Wooliver, C, Heidel, RE, Adams, S, Dunlap, J, Ramirez-Alvarado, M, Blancas-Mejia, LM, Lands, RH, Kennel, SJ & Wall, JS 2017, 'Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity', PLoS One, vol. 12, no. 3, e0174152. https://doi.org/10.1371/journal.pone.0174152
Martin, Emily B. ; Williams, Angela ; Wooliver, Craig ; Heidel, R. Eric ; Adams, Sarah ; Dunlap, John ; Ramirez-Alvarado, Marina ; Blancas-Mejia, Luis M. ; Lands, Ronald H. ; Kennel, Stephen J. ; Wall, Jonathan S. / Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity. In: PLoS One. 2017 ; Vol. 12, No. 3.
@article{0c930c0de5984ef5828ac560612170b7,
title = "Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity",
abstract = "Background Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed of proteinaceous fibrils and extracellular matrix proteins found in all patients with AL and in ~10±30{\%} of patients who presented with MM. Amyloid deposits systemically in multiple organs and tissues leading to dysfunction and ultimately death. The overall survival of patients with amyloidosis is worse than for those with early stage MM. Methods and findings We have developed a sensitive binding assay quantifying the recruitment of full length, patient-derived LC proteins by synthetic amyloid fibrils, as a method for studying their amyloidogenic potential. In a survey of eight urinary LC, both AL and MM-associated proteins were recruited by synthetic amyloid fibrils; however, AL-associated LC bound significantly more efficiently (p < 0.05) than did MM LCs. The LC proteins used in this study were isolated from urine and presumed to represent a surrogate of serum free light chains. Conclusion The binding of LC to synthetic fibrils in this assay accurately differentiated LC with amyloidogenic propensity from MM LC that were not associated with clinical amyloid disease. Notably, the LC from a MM patient who subsequently developed amyloid behaved as an ALassociated protein in the assay, indicating the possibility for identifying MM patients at risk for developing amyloidosis based on the light chain recruitment efficacy. With this information, at risk patients can be monitored more closely for the development of amyloidosis, allowing timely administration of novel, amyloid-directed immunotherapiesthis approach may improve the prognosis for these patients.",
author = "Martin, {Emily B.} and Angela Williams and Craig Wooliver and Heidel, {R. Eric} and Sarah Adams and John Dunlap and Marina Ramirez-Alvarado and Blancas-Mejia, {Luis M.} and Lands, {Ronald H.} and Kennel, {Stephen J.} and Wall, {Jonathan S.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1371/journal.pone.0174152",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Differential recruitment efficacy of patientderived amyloidogenic and myeloma light chain proteins by synthetic fibrilsA metric for predicting amyloid propensity

AU - Martin, Emily B.

AU - Williams, Angela

AU - Wooliver, Craig

AU - Heidel, R. Eric

AU - Adams, Sarah

AU - Dunlap, John

AU - Ramirez-Alvarado, Marina

AU - Blancas-Mejia, Luis M.

AU - Lands, Ronald H.

AU - Kennel, Stephen J.

AU - Wall, Jonathan S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed of proteinaceous fibrils and extracellular matrix proteins found in all patients with AL and in ~10±30% of patients who presented with MM. Amyloid deposits systemically in multiple organs and tissues leading to dysfunction and ultimately death. The overall survival of patients with amyloidosis is worse than for those with early stage MM. Methods and findings We have developed a sensitive binding assay quantifying the recruitment of full length, patient-derived LC proteins by synthetic amyloid fibrils, as a method for studying their amyloidogenic potential. In a survey of eight urinary LC, both AL and MM-associated proteins were recruited by synthetic amyloid fibrils; however, AL-associated LC bound significantly more efficiently (p < 0.05) than did MM LCs. The LC proteins used in this study were isolated from urine and presumed to represent a surrogate of serum free light chains. Conclusion The binding of LC to synthetic fibrils in this assay accurately differentiated LC with amyloidogenic propensity from MM LC that were not associated with clinical amyloid disease. Notably, the LC from a MM patient who subsequently developed amyloid behaved as an ALassociated protein in the assay, indicating the possibility for identifying MM patients at risk for developing amyloidosis based on the light chain recruitment efficacy. With this information, at risk patients can be monitored more closely for the development of amyloidosis, allowing timely administration of novel, amyloid-directed immunotherapiesthis approach may improve the prognosis for these patients.

AB - Background Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed of proteinaceous fibrils and extracellular matrix proteins found in all patients with AL and in ~10±30% of patients who presented with MM. Amyloid deposits systemically in multiple organs and tissues leading to dysfunction and ultimately death. The overall survival of patients with amyloidosis is worse than for those with early stage MM. Methods and findings We have developed a sensitive binding assay quantifying the recruitment of full length, patient-derived LC proteins by synthetic amyloid fibrils, as a method for studying their amyloidogenic potential. In a survey of eight urinary LC, both AL and MM-associated proteins were recruited by synthetic amyloid fibrils; however, AL-associated LC bound significantly more efficiently (p < 0.05) than did MM LCs. The LC proteins used in this study were isolated from urine and presumed to represent a surrogate of serum free light chains. Conclusion The binding of LC to synthetic fibrils in this assay accurately differentiated LC with amyloidogenic propensity from MM LC that were not associated with clinical amyloid disease. Notably, the LC from a MM patient who subsequently developed amyloid behaved as an ALassociated protein in the assay, indicating the possibility for identifying MM patients at risk for developing amyloidosis based on the light chain recruitment efficacy. With this information, at risk patients can be monitored more closely for the development of amyloidosis, allowing timely administration of novel, amyloid-directed immunotherapiesthis approach may improve the prognosis for these patients.

UR - http://www.scopus.com/inward/record.url?scp=85016265701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016265701&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0174152

DO - 10.1371/journal.pone.0174152

M3 - Article

C2 - 28350808

AN - SCOPUS:85016265701

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0174152

ER -